Exane Derivatives Satsuma Pharmaceuticals, Inc. Transaction History

Exane Derivatives

  • $157 Million
  • Q2 2022

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 27, 2021
SELL
$3.56 - $5.09 $14,517 - $20,757
-4,078 Closed
0 $0
Q3 2020

Oct 06, 2020
SELL
$3.85 - $28.47 $269 - $1,992
-70 Reduced 1.69%
4,078 $15,000
Q1 2020

Apr 17, 2020
BUY
$14.53 - $30.69 $60,270 - $127,302
4,148 New
4,148 $89,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email